Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Formatting issues with Eisai's original rufinamide anti-epilepsy NDA could result in a more than two-month delay in approval
You may also be interested in...
Eisai May Resubmit Aricept Severe Alzheimer’s sNDA In Electronic Format
Eisai is considering an electronic format for a mid-December resubmission of an sNDA for Aricept treatment of severe Alzheimer’s disease.
Eisai rufinamide NDA
Eisai is seeking two indications for its anti-epileptic rufinamide: adjunctive therapy for Lennox-Gastaut syndrome in children ages four and up and adjunctive therapy for partial-onset seizures with and without secondary generalization in adults and adolescents ages 12 and over. The firm submitted the NDA for the triazole derivative Sept. 9, putting a standard review deadline at July 9, 2006. The two pivotal trials supporting the indications were conducted by innovator Novartis. Rufinamide is "structurally distinct from currently approved [anti-epileptic drugs]," Eisai notes. The agent was granted orphan status for Lennox-Gastaut in October 2004...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011